Which diseases are suitable for the treatment of veentuzumab/besifu?

Enfortumab is an antibody-drug conjugate (ADC) targeting the Nectin-4 receptor. It is mainly used in advanced or metastatic urothelial carcinoma (urothelial carcinoma; bladder cancer), especially in patients who have progressed after previous platinum-based chemotherapy or immune checkpoint inhibitor therapy. In urothelial cancer, Nectin-4 receptors are widely expressed, allowing venetuzumab to bind to cancer cells with high selectivity and kill tumor cells through antibody-mediated release of intracellular toxins, thereby achieving precise treatment.

Clinical studies have shown that veentuzumab can significantly improve tumor response rate and survival benefit in the treatment of urothelial cancer patients such as advanced bladder cancer, renal pelvis cancer, and urethral cancer, providing a new treatment option for patients with chemotherapy resistance or immunotherapy failure. In addition to single-agent use, veentuzumab can also be used in combination with other anti-cancer drugs, such as with PD-1/PD-L1 inhibitors or chemotherapy regimens, to enhance the anti-tumor effect. Its mechanism of action is to not only inhibit the proliferation of cancer cells, but also destroy tumor tissue through the release of cytotoxicity. At the same time, it is highly selective for normal cells and reduces the risk of systemic side effects.

In addition, veentuzumab also has certain specificity in patient group selection. Clinical guidelines recommend that patients with advanced urothelial cancer with high Nectin-4 expression and progression despite previous standard treatments should be given priority. The study also found that early identification of patients with high expression of Nectin-4 and early intervention with veentuzumab treatment can help improve the response rate and prolong progression-free survival. Generally speaking, the indications of veentuzumab are mainly advanced, recurrent or drug-resistant urothelial cancer, providing a new treatment option for this high-risk patient group.

As clinical experience accumulates and global approval expands, veentuzumab may play a broader role in the future as combination therapy, postoperative adjuvant, or in specific subgroups of high-risk patients.

Reference: https://www.padcev.com/